Literature DB >> 31734366

Therapeutic applications of AS1411 aptamer, an update review.

Rezvan Yazdian-Robati1, Payam Bayat2, Fatemeh Oroojalian3, Mehryar Zargari1, Mohammad Ramezani4, Seyed Mohammad Taghdisi5, Khalil Abnous6.   

Abstract

Nucleolin or C23, is one of the most abundant non-ribosomal phosphoproteins of nucleolus. However, in several cancers, nucleolin is highly expressed both intracellularly and on the cell surface. So, it is considered as a potential target for the diagnosis and cancer therapy. Targeting nucleolin by compounds such as AS1411 aptamer can reduce tumor cell growth. In this regard, interest has increased in nucleolin as a molecular target for overcoming cancer therapy challenges. This review paper addressed recent progresses in nucleolin targeting by the G-rich AS1411 aptamer in the field of cancer therapy mainly over the past three years.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AS1411 aptamer; Nucleolin; Targeted therapy

Mesh:

Substances:

Year:  2019        PMID: 31734366     DOI: 10.1016/j.ijbiomac.2019.11.118

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  22 in total

1.  Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy.

Authors:  Husun Qian; Yixin Fu; Minkang Guo; Yu Chen; Dian Zhang; Yu Wei; Fangfang Jin; Qian Zeng; Yange Wang; Chengsen Chai; Shijia Ding; Wei Cheng; Tingmei Chen
Journal:  Mol Ther       Date:  2022-04-21       Impact factor: 12.910

2.  Overexpression of Nucleolin and Associated Genes in Prostate Cancer.

Authors:  Virginie Firlej; Pascale Soyeux; Maya Nourieh; Eric Huet; Fannie Semprez; Yves Allory; Arturo Londono-Vallejo; Alexandre de la Taille; Francis Vacherot; Damien Destouches
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

3.  NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs.

Authors:  Tyler Sheetz; Joseph Mills; Anna Tessari; Megan Pawlikowski; Ashley E Braddom; Tasha Posid; Debra L Zynger; Cindy James; Valerio Embrione; Kareesma Parbhoo; Claudia Foray; Vincenzo Coppola; Carlo M Croce; Dario Palmieri
Journal:  Cancers (Basel)       Date:  2020-07-10       Impact factor: 6.639

4.  Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy.

Authors:  Chiara Brignole; Veronica Bensa; Nuno A Fonseca; Genny Del Zotto; Silvia Bruno; Ana F Cruz; Fabiana Malaguti; Barbara Carlini; Fabio Morandi; Enzo Calarco; Patrizia Perri; Vera Moura; Laura Emionite; Michele Cilli; Francesco De Leonardis; Annalisa Tondo; Loredana Amoroso; Massimo Conte; Alberto Garaventa; Angela R Sementa; Maria V Corrias; Mirco Ponzoni; Joao N Moreira; Fabio Pastorino
Journal:  J Exp Clin Cancer Res       Date:  2021-06-02

Review 5.  Advances in Screening and Development of Therapeutic Aptamers Against Cancer Cells.

Authors:  Zheng Li; Xuekun Fu; Jie Huang; Peiyuan Zeng; Yuhong Huang; Xinxin Chen; Chao Liang
Journal:  Front Cell Dev Biol       Date:  2021-05-19

Review 6.  Recent Advances in Conventional Methods and Electrochemical Aptasensors for Mycotoxin Detection.

Authors:  Jing Yi Ong; Andrew Pike; Ling Ling Tan
Journal:  Foods       Date:  2021-06-22

Review 7.  Aptamers: Cutting edge of cancer therapies.

Authors:  Sarah Shigdar; Brett Schrand; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2021-06-17       Impact factor: 12.910

Review 8.  Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.

Authors:  Valentina Giudice; Francesca Mensitieri; Viviana Izzo; Amelia Filippelli; Carmine Selleri
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923

9.  Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin.

Authors:  Fengjiao Yao; Yacong An; Xundou Li; Zhaoyi Li; Jinhong Duan; Xian-Da Yang
Journal:  Int J Nanomedicine       Date:  2020-03-27

Review 10.  Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.

Authors:  Q Li; S H Maier; P Li; J Peterhansl; C Belka; J Mayerle; U M Mahajan
Journal:  Radiat Oncol       Date:  2020-08-05       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.